Pharma-Bio Serv Debt-to-EBITDA Ratio Growth & History (PBSV)

Pharma-Bio Serv's debt-to-ebitda ratio was 0.30 for fiscal 2023.

View full Pharma-Bio Serv company overview

Pharma-Bio Serv annual debt-to-ebitda ratio history

Pharma-Bio Serv annual debt-to-ebitda ratio

Fiscal yearPeriod endedDebt-to-EBITDA ratioChangeGrowth
20232023-10-310.30−0.10−25.21%
20222022-10-310.40
20202020-10-310.370.33+755.23%
20192019-10-310.04
20162016-10-310.240.20+573.36%
20152015-10-310.030.01+17.09%
20142014-10-310.030.02+128.19%
20132013-10-310.01−0.01−35.80%
20122012-10-310.02−0.01−37.71%
20112011-10-310.03−0.04−57.73%
20102010-10-310.08

Pharma-Bio Serv debt-to-ebitda ratio trends

Between the periods ended 2010-10-31 and 2023-10-31, Pharma-Bio Serv's debt-to-ebitda ratio increased from 0.08 to 0.30, a change of 0.22. The latest reported quarter, Q1 2024, shows 5.21.

About the metric

What the debt-to-EBITDA ratio means

Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.

Calculation and source

How debt-to-EBITDA is calculated

TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Pharma-Bio Serv source filings ↗

Community posts

It’s quiet here.

No posts about PBSV yet. Start the conversation.

Write the first post